(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 September 2021 (23.09.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/188681 A1

(51) International Patent Classification:
A61K 35/17 (2015.01) *A61K 47/64* (2017.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2021/022779

(22) International Filing Date:
17 March 2021 (17.03.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

202010188038.1	17 March 2020 (17.03.2020)	CN
16/877,069	18 May 2020 (18.05.2020)	US
PCT/CN2020/109645	17 August 2020 (17.08.2020)	CN
63/154,032	26 February 2021 (26.02.2021)	US

(71) Applicants: **CELLULAR BIOMEDICINE GROUP HK LIMITED** [CN/CN]; Room 417, 4th Floor, Lippo Centre, Tower Two, No.89 Queensway, Admiralty, Hong Kong (CN). **SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.** [CN/CN]; Building 3, 85 Faladi Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, 201210 (CN). **WUXI CELLULAR BIOPHARMACEUTICAL GROUP LTD.** [CN/CN]; 1699 Huishan Road, Building 7, 1st Floor A Area, Wuxi Huishan Economic Development Zone, Wuxi, Jiangsu, 214174 (CN). **CELLULAR BIOMEDICINE GROUP INC.** [US/US]; 9605 Medical Center Drive, Suite 100, Rockville, MD 20850 (US).

(72) Inventors: **YAO, Yihong**; Room 417, 4th Floor, Lippo Centre, Tower Two, No.89 Queensway, Admiralty, Hong Kong (CN). **HUANG, Jiaqi**; Room 417, 4th Floor, Lippo Centre, Tower Two, No.89 Queensway, Admiralty, Hong Kong (CN). **YAO, Xin**; Room 417, 4th Floor, Lippo Centre, Tower Two, No.89 Queensway, Admiralty, Hong Kong (CN). **ZHU, Shigui**; Room 417, 4th Floor, Lippo Centre, Tower Two, No.89 Queensway, Admiralty, Hong Kong (CN).

(74) Agent: **DAVITZ, Michael, A.** et al.; Leason Ellis LLP, One Barker Avenue, Fifth Floor, White Plains, NY 10601 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: COMBINED CHIMERIC ANTIGEN RECEPTOR TARGETING CD19 AND CD20 AND APPLICATIONS THEREOF




FIG. 1

(57) Abstract: The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and a scFv targeting CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention targets CD19 and/or CD20 positive cells and can be used to treat CD19 and/or CD20 positive B- cell lymphoma, leukemia and other diseases.

WO 2021/188681 A1

[Continued on next page]

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*